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Abstract
Background: Castleman disease (CD) is a rare benign disorder characterised by hyperplasia of lymphoid tissue that
may develop at a single site or throughout the body. The etiology of this disorder is unclear, although the
histopathological presentation can be differentiated into a hyaline vascular variant, a plasma cell variant and a
mixed variant. Clinically, it has been recorded that 3 manifestations of CD are characterized: a localized unicentric
type, a generalized multicentric type and a mixed form. Surgery remains the main treatment for resectable
unicentric CD, since removal of the large node is possible without further complications. No consensus has been
reached concerning the most adequate treatment for irresectable unicentric CD.
Methods: Case report of a 67 year old woman.
Results: This report, describes the case of a 67-year-old woman with unicentric Castleman disease located in the
right lower abdomen. The patient had symptoms of fatigue, dyspnoea and pain in the right lower abdomen.
Computed tomography (CT)- examination revealed a tumour, which had grown to form a close relationship with
the common iliac vessels and the sacral bone. A Laparotomy procedure revealed that the tumour was an
irresectable mass. Neo-adjuvant radiotherapy (40 Gy) was administered in order to downsize the tumour. Six weeks
later a new CT-scan revealed a major reduction of the tumour, which enabled a successful radical resection of the
tumour to be performed. Histopathological analysis of the tumour showed the hyaline vascular type of CD.
Conclusions: Neo-adjuvant radiotherapy should be considered in case of an irresectable unicentric CD.
Background
In 1954, Benjamin Castleman described an unusual
benign disorder that was characterized by hyperplasia of
lymphoid tissue [1]. A couple of years later, Castleman
et al [2] published more cases with benign massive
growth of lymph nodes that is commonly referred to as
Castleman’s disease (CD). Flendrig et al [3] categorised
two main types and one mixed variant of CD. Keller et
al [4] defined these histopathological different patterns.
The first being a hyaline vascular type (HV), charac-
terized by lymphoid follicular hyperplasia with involuted
germinal centres, which are partly or totally replaced by
deposit of hyaline material and transfixed by a radially
penetrating vessel, characterized as a ‘lolly pop’
structure. The second variant was defined as the plasma
cell type (PC) with a follicular hyperplasia of hyperplas-
tic, large germinal centres in which the interfollicular
areas were occupied by large sheets of plasma cells.
Clinically a broad spectrum of manifestations of CD
are described, ranging from an asymptomatic localized
lymphadenopathy to a severe symptomatic multifocal or
generalized lymphadenopathy [5]. A commonly used
system to classify the heterogeneity of CD was proposed
b yM c C a r t ye ta li n1 9 9 5[ 6 ] .T h i sm a d ead i s t i n c t i o n
between the unicentric and the multicentric forms of
disease. This classification correlates quite well with the
histopathologically variants. As the HV type is mostly
unicentric and the PC type and the mixed variant seem
to be mostly multicentric [7,8].
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associated with local involvement of surrounding struc-
tures or because of the systemic effects associated with
the multicentric form such as fever, weight loss, exces-
sive sweating, hemolytic anaemia, splenomegaly, oedema
and neuropathy.
CD can also be associated with HIV infection, POEMS
syndrome, amyloidosis, renal insufficiency and increased
risk of lymphoma [5,9-11], these conditions necessitate
diagnostic and therapeutic intervention.
Surgery is considered to be the most adequate therapy
for unicentric resectable cases of CD, as it seems to be
curative in almost all of the cases [4,6,12-20]. Radiother-
apy has also been described as a definitive treatment,
however with a variable response rate [4,9,10,21-30].
No consensus has been reached concerning the most
adequate treatment for irresectable CD. To our knowl-
edge, neo-adjuvant radiotherapy to downsize primary
irresectable CD in order to achieve a radical surgical
resection has not been described yet. This paper reviews
the associated literature concerning the treatment of CD
and describes a case history of an irresectable unicentric
localisation of CD which was treated with neo-adjuvant
radiotherapy and subsequent radical resection.
Methods
Case presentation
A 67-year-old woman with a history of hyperthyroidism,
proptosis and anaemia was referred to the internal med-
icine department with complaints of weight loss, fatigue,
dyspnea and pain in the right lower abdomen. Physical
examination revealed a painful palpable mass in the
right lower quadrant of the abdomen.
Ultrasonography of the abdomen showed a multicys-
tic, solid structure in the right lower abdomen. Subse-
quent Computed Tomography (CT) imaging of the
abdomen showed right ventrally of the body of the first
sacral vertebrum a partly solid, partly cystic tumour of
71 × 51 mm with oedematous infiltration of the sur-
rounding adipose tissue and a close relationship with
the common iliac artery and vein (figure 1A). Since the
radiological aspect was initially presumed to be indica-
tive of ovarian cancer, the patient was referred for
gynaecological examination. Transvaginal ultrasound
showed a polycystic structure on the right side. CA125
was normal. The patient underwent a staging laparot-
omy by the gynaecologist, revealing a normal uterus,
normal ovaries and a fixed retroperitoneal tumour
located to the right side of the aortic bifurcation. A sur-
geon oncologist was consulted, and because of the fixa-
tion and close relationship of the tumour to the iliac
vessels and sacral bone, the tumour was regarded as pri-
mary irresectable and only an incisional biopsy was per-
formed to obtain material for histological examination.
Histopathology from the specimen revealed lymphoid
hyperplasia, atrophic germinal centers and radialy pene-
trating vessels (lollypop phenomenon) as seen in the HV
variant of CD, (figure 2). A subsequent positron emis-
sion tomogram (PET)-scan revealed no signs of dissemi-
nated disease. There were no laboratory abnormalities
and the HIV test turned out to be negative. Since the
tumour was regarded irresectable, neo-adjuvant radio-
therapy was proposed in order to downsize the tumour
to achieve a radical surgical excision. Neo-adjuvant
radiotherapy was delivered by means of a 4-field techni-
que to a dose of 40 Gy in 20 fractions of 2 Gy. Six
weeks later a CT-scan, revealed a major downsizing
with a maximal diameter of the tumour of 47 mm,
which was initially 72 mm (figure 1B). A subsequent
laparotomy revealed a mobile tumour and a radical
resection was performed without complications. An
intraoperative boost (IORT) of 10 Gy was applied to the
presacral resection surface. The patient recovered with-
out complications and final histology showed a cystic
residual localisation of CD of the HV type with free
resection margins. At present, two years and 3 months
after resection of the tumour no signs of recurrence
have been detected.
Discussion
This report documents a unique case of a primary irre-
sectable case of the HV unicentric type of CD which
was treated with neoadjuvant radiotherapy and subse-
quent successful radical resection. To our knowledge,
there is no report in the literature describing neoadju-
vant radiotherapy as part of the treatment of unicentric
CD.
T h ee t i o l o g yo fC a s t l e m a n ’sD i s e a s ei su n k n o w n .
However, CD is associated with other disorders such as
HIV infection, POEMS syndrome, amyloidosis, renal
insufficiency and increased risk of lymphoma [5,9-11].
Therefore specific systemic therapy related to the asso-
ciated disorder is indicated. There is no consensus yet
concerning the most adequate treatment for CD. Sur-
gery is considered to be the most adequate therapy for
unicentric cases of CD as it seems to be curative in
most of the cases [4,6,12-20]. Various strategies have
been described in case of irresectable unicentric CD ran-
ging from primary radiotherapy, incomplete resection
[10] and chemotherapy [31].
Primary radiotherapy has been described in numerous
case reports and small case series as one of the strate-
gies for the treatment of both unicentric and multi-
centric forms of CD. Keller et al [4] however described
that in 4 cases primary radiotherapy had only a minimal
effect and concluded that radiotherapy alone was not
effective. However, several cases have been reported
with significant responses to primary radiotherapy, for
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[9,10,21-23,25-30,32,33]. Table 1, presents an overview
of all studies that have evaluated the use of primary
radiotherapy in CD, both for unicentric and multicentric
disease, with doses ranging from 12 to 50 Gy
[4,8-10,22-30,32,34,35]. Responses to primary radiother-
apy for the treatment of both forms of CD ranged from
no response to a complete response. Nevertheless, 88%
of all CD patients treated with radiotherapy showed a
response, of which 43,8% showed a complete response.
With respect to the dose of radiotherapy, no correla-
tion can be observed between dose and response. Most
patients were treated with a dose between 40 and 50
Gy, however patients with a complete response received
a dose between 12 Gy and 50 Gy.
The evidence in the current literature reveals that
radical surgery results in excellent rates of cure
[4,6,12-19]. Also the literature reports excellent response
rates with primary radiotherapy (table 1). Therefore it
was concluded that, in case of an irresectable presenta-
tion of unicentric CD, surgery after neoadjuvant radio-
therapy was a possible strategy. This case illustrates that
this hypothesis was successful and should be considered
as a strategy in case of irresectable unicentric disease.
The question remains which policy should be followed
in case of a complete radiologic response. Although
merely speculative, a wait and see policy with regular
radiological follow-up could be a reasonable strategy in
case of no systemic symptoms, since most reports
describe unicentric CD as a slowly progressive disease,
w h i c hd o e sn o tm e t a s t a s i z e .I nt h ec a s ew h e r ear e c u r -
rence of residual disease is found, a resection in an early
stage could still be performed. In that case we propose a
frequent follow up, using CT scanning every six months,
since unicentric CD is a slowly progressive disease. In
case of a partial response to primary radiotherapy, we
suggest that surgical resection is strongly recommended,
since radical surgery can potentially cure unicentric CD.
Surgery was performed six weeks after the last radio-
therapy dose. The rationale for this interval is based on
the experience gained from treatments with other
neoadjuvant strategies in solid tumours [36].
Different types of therapy have been described for the
treatment of patients with multicentric CD. However
the treatment strategy for this variant of CD is not
within the scope of this article. Nevertheless, the litera-
ture reveals that primary radiotherapy can also achieve a
remission of symptoms [10,24,26,28,30,32] and given the
fact that multicentric CD, more often then unicentric
CD, causes generalised symptoms, radiotherapy could
also be used as a symptomatic treatment.
The rationale of our additional intra-operative radio-
therapy (IORT) boost was based on the close
Figure 1 A: Computed Tomography (CT) of the abdomen showing the tumour and its relationship with the sacral vertebrum, the
adipose tissue and the common iliac artery and vein, before neo-adjuvant radiotherapy. B: Computed Tomography (CT) of the
abdomen showing the marked downsizing of the tumour, after neo-adjuvant radiotherapy.
Figure 2 Histopathology showing lymphoid hyperplasia,
atrophic germinal centers and radialy penetrating vessels
(lollypop phenomenon) as seen in the HV variant of CD.
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was analogous to our management of other locally
advanced solid tumours like rectal cancer and soft tissue
sarcomas [37-40].
Conclusion
I nt h i sc a s er e p o r ti ti sd e m o n s t r a t e dt h a tn e o - a d j u v a n t
radiotherapy in case of locally advanced irresectable uni-
centric CD facilitates a radical resection. Therefore, ana-
logous with the treatment of other locally advanced
solid tumours, neo-adjuvant radiotherapy with a dose of
40-50 Gy and a subsequent resection 6 weeks later
should be considered if an irresectable unicentric variant
of CD is encountered.
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